Wockhardt · NSE: WOCKPHARMA · BSE: 532300
Q1 FY22 results · Apr–Jun 2021
Wockhardt reported revenue from operations of ₹859.55 crore (up 43.7% from Q1 FY21) and net loss of ₹6.58 crore for Q1 FY22 (Apr–Jun 2021), on a consolidated basis.
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 859.55 | 598.27 | +43.7% | 631.96 | +36.0% |
| Other income | 1.65 | 7.95 | −79.2% | 7.54 | −78.1% |
| Total income | 861.20 | 606.22 | +42.1% | 639.50 | +34.7% |
| Profit before tax | (6.00) | (336.24) | Loss narrowed | (178.18) | Loss narrowed |
| Net profit for the period | (6.58) | 759.75 | Turned loss | (106.84) | Loss narrowed |
| Attributable to shareholders of the company | (12.71) | 760.06 | Turned loss | (92.79) | Loss narrowed |
| EPS, basic (₹) | (1.15) | 68.64 | Turned loss | (8.38) | Loss narrowed |
| Net margin (%) | -0.8 | 127.0 | -16.9 |
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 278.95 | 177.58 | +57.1% | 261.75 | +6.6% |
| Other income | 3.15 | 9.74 | −67.7% | 6.31 | −50.1% |
| Total income | 282.10 | 187.32 | +50.6% | 268.06 | +5.2% |
| Profit before tax | (77.57) | (332.98) | Loss narrowed | (113.24) | Loss narrowed |
| Net profit for the period | (48.69) | 766.39 | Turned loss | (47.05) | Loss widened |
| EPS, basic (₹) | (4.40) | 69.21 | Turned loss | (4.25) | Loss widened |
| Net margin (%) | -17.5 | 431.6 | -18.0 |
Consolidated
- Filed with BSE
- 22 Jul 2021, 20:28 IST
- Board meeting
- 22 Jul 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 22 Jul 2021, 20:28 IST
- Board meeting
- 22 Jul 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE